SCHEMBL8449337

SCHEMBL8449337

COC(=O)/C=C/C(=O)OC(C)(C)C

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 3/20 0.65
HCAR2 Q8TDS4 2/20 0.65
KEAP1 Q14145 1/20 0.65
DGAT1 O75907 1/20 0.44
ALDH1A1 P00352 4/20 0.38
MAPT P10636 2/20 0.38
KDM4E B2RXH2 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
TYR P14679 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
CA14 Q9ULX7 1/20 0.36
GFPT1 Q06210 1/20 0.36
ALOX15 P16050 1/20 0.35
RECQL P46063 1/20 0.35
HSD17B10 Q99714 1/20 0.35
NR1H4 Q96RI1 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8449347 1.00 NFE2L2 (0.65) NFE2L2HCAR2KEAP1DGAT1ALDH1A1
SCHEMBL8451389 1.00 NFE2L2 (0.65) NFE2L2HCAR2KEAP1DGAT1ALDH1A1
SCHEMBL43004 0.89 HCAR2 (0.45) NFE2L2HCAR2KEAP1DGAT1ALDH1A1
SCHEMBL43764 0.89 HCAR2 (0.45) NFE2L2HCAR2KEAP1DGAT1ALDH1A1
SCHEMBL375029 0.89 HCAR2 (0.45) NFE2L2HCAR2KEAP1DGAT1ALDH1A1
SCHEMBL19008840 0.82 HCAR2 (0.39) NFE2L2HCAR2KEAP1DGAT1LMNA
Dimethyl Fumarate SCHEMBL29110379 0.81 NFE2L2 (0.77) NFE2L2HCAR2KEAP1ALDH1A1MAPT
Dimethyl Maleate SCHEMBL75864 0.81 NFE2L2 (1.00) NFE2L2HCAR2KEAP1ALDH1A1MAPT
Dimethyl Fumarate SCHEMBL41836 0.81 NFE2L2 (1.00) NFE2L2HCAR2KEAP1ALDH1A1MAPT
Dimethyl Fumarate SCHEMBL11668350 0.81 NFE2L2 (1.00) NFE2L2HCAR2KEAP1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5608011-A Crosslinkable polymer powder compositions WACKER-CHEMIE GMBH (DE) 1997-03-04 US claimed
EP-0702059-B1 Crosslinked polymer-powder compositions WACKER CHEMIE GMBH (DE) 1996-12-18 EP claimed
US-9988340-B2 Compositions and methods for the treatment of multiple sclerosis CELLIX BIO PRIVATE LIMITED (IN) 2018-06-05 US disclosed
US-9932294-B2 Compositions and methods for the treatment of multiple sclerosis CELLIX BIO PRIVATE LIMITED (IN) 2018-04-03 US disclosed
US-9580383-B2 Compositions and methods for the treatment of multiple sclerosis CELLIX BIO PRIVATE LIMITED (IN) 2017-02-28 US disclosed
US-9498461-B2 Compositions and methods for the treatment of inflammatory bowel disease CELLIX BIO PRIVATE LIMITED (IN) 2016-11-22 US disclosed
US-9499526-B2 Compositions and methods for the treatment of neurologic diseases CELLIX BIO PRIVATE LIMITED (IN) 2016-11-22 US disclosed
US-9434704-B2 Compositions and methods for the treatment of neurological degenerative disorders CELLIX BIO PRIVATE LIMITED (IN) 2016-09-06 US disclosed
US-9434729-B2 Compositions and methods for the treatment of periodontitis and rheumatoid arthritis CELLIX BIO PRIVATE LIMITED (IN) 2016-09-06 US disclosed
US-20160152553-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS CELLIX BIO PRIVATE LIMITED (IN) 2016-06-02 US disclosed
US-9333187-B1 Compositions and methods for the treatment of inflammatory bowel disease CELLIX BIO PRIVATE LIMITED (IN) 2016-05-10 US disclosed
US-20130299747-A1 CURATIVES FOR EPOXY COMPOSITIONSERS DESIGNER MOLECULES, INC. 2013-11-14 US disclosed
US-20130199724-A1 CURATIVES FOR EPOXY COMPOSITIONS DESIGNER MOLECULES, INC. (US) 2013-08-08 US disclosed
US-8344076-B2 Prepared by the reaction of an epoxy compound and a reactive ester; adhesive DESIGNER MOLECULES, INC. (US) 2013-01-01 US disclosed
US-20100113643-A1 CURATIVES FOR EPOXY ADHESIVE COMPOSITIONS DESIGNER MOLECULES, INC. (US) 2010-05-06 US disclosed
US-20080142158-A1 HYDROLYTICALLY RESISTANT THERMOSET MONOMERS DESIGNER MOLECULES, INC. 2008-06-19 US disclosed
US-5880239-A Fusible chlorine-free vinyl acetate copolymer fibres WACKER-CHEMIE GMBH (DE) 1999-03-09 US disclosed
EP-0460769-B1 Semi-permeable composite membrane and process for manufacturing same X FLOW BV (NL) 1998-05-13 EP disclosed
US-5608011-A Crosslinkable polymer powder compositions WACKER-CHEMIE GMBH (DE) 1997-03-04 US disclosed
EP-0460769-A1 Semi-permeable composite membrane and process for manufacturing same X-Flow B.V. (NL) 1991-12-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160152553-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS HLA-DRB1, SI, PMP22 NFE2L2 1945/4885HCAR2 697/4885KEAP1 2114/4885
US-20080142158-A1 HYDROLYTICALLY RESISTANT THERMOSET MONOMERS ESD, JMJD7, PCNA NFE2L2 3033/4885HCAR2 2286/4885KEAP1 1793/4885
US-20100113643-A1 CURATIVES FOR EPOXY ADHESIVE COMPOSITIONS ALOX5, LTC4S, ALOX15B NFE2L2 879/4885HCAR2 443/4885KEAP1 680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.